MedTrace Logo

The Hong Kong CML Registry

NCT03625583 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2018-08-10

No results posted yet for this study

Summary

Chronic myeloid leukaemia (CML) is a malignant disorder of the haematopoietic system. It is characterized by the chromosomal translocation between chromosomes 9 and 22, resulting in the formation of the Philadelphia chromosome which contains the BCRABL1 fusion gene. The projected prevalence of CML is rising steadily, due to the significantly improved survival of CML patients and that the incidence rate increases with age. The efficacious yet costly tyrosine kinase inhibitors pose a significant financial burden to both patients and the health care system, while they carry their own side effects and long-term risks. This study aims to set up a local disease registry of CML to improve the knowledge concerning this disease, including epidemiology,characteristics and treatment outcome of CML in Hong Kong,as well as long-term safety and toxicities of therapeutic agents.

Conditions

  • Chronic Myeloid Leukemia

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Dr Carol Cheung, MBBS · Queen Mary Hospital, Hong Kong

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2023-03-31
Completion
2023-09-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03625583 on ClinicalTrials.gov